Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has found. The anti-obesity injections could reduce the risk in obese people ...
Find your bookmarks in your Independent Premium section, under my profile Weight loss jabs like Ozempic can cut the risk of heart attacks or strokes by a fifth, a “game-changing” new study has ...
Anti-obesity jabs could reduce the risk of heart attacks, strokes or heart failure in obese people regardless of the amount of weight they lose while on the drug, researchers have found.
A groundbreaking study has revealed that an anti-obesity jab containing semaglutide, a drug used to treat obesity, significantly reduces the risk of heart attacks and strokes, regardless of the ...
A weight loss injection could reduce the risk of heart attacks and benefit the cardiovascular health of adults, according to a study on what could be the largest medical breakthrough since statins.
Obesity jabs could cut the risk of heart attacks and strokes in people even if they fail to lose much weight, according to an analysis of a study funded by a drug manufacturer. Researchers looked ...
Anti-obesity injections could lower the chances of serious heart disease in overweight individuals, regardless of their weight loss while on the medication, according to new research. A new study ...
An anti-obesity drug could have additional health benefits including reducing the risk of heart attacks and strokes a new study has revealed. A five-year study was carried out by a team led ...
Semaglutide, also known as Ozempic or Wegovy, is set to transform treatments for cardiovascular disease, but a change in ...
Delivered via an injection into the skin, the drug makes people feel fuller and more satisfied, so they eat less Obesity jabs could cut the risk of heart attacks and strokes in people even if they ...
The five-year study explored if the drug sold under the brand names Wegovy, Ozempic and Rybelsus could reduce the risk of heart attacks or stroke in obese people without diabetes. It comprised ...
Patients taking semaglutide had a 20% lower risk of heart attack, stroke or death due to cardiovascular disease after three years of treatment, according to an analysis of data from the five-year ...